P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)

• Michael Gulrajani,
• Tracy Clevenger,
• Jean Cheung,
• Fanny Krantz,
• Cynthia Nguyen,
• Miranda Luarca,
• Cecile Krejsa,
• Wayne P. Rothbaum,
• Todd Covey

Affiliations

Michael Gulrajani

1 Telios Pharma, Inc., Redwood City, CA, United States

Tracy Clevenger

1 Telios Pharma, Inc., Redwood City, CA, United States

Jean Cheung

1 Telios Pharma, Inc., Redwood City, CA, United States

Fanny Krantz

1 Telios Pharma, Inc., Redwood City, CA, United States

Cynthia Nguyen

1 Telios Pharma, Inc., Redwood City, CA, United States

Miranda Luarca

1 Telios Pharma, Inc., Redwood City, CA, United States

Cecile Krejsa

1 Telios Pharma, Inc., Redwood City, CA, United States

Wayne P. Rothbaum

1 Telios Pharma, Inc., Redwood City, CA, United States

Todd Covey

1 Telios Pharma, Inc., Redwood City, CA, United States